Viatris Revenue 2010-2024 | VTRS
Viatris annual/quarterly revenue history and growth rate from 2010 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Viatris revenue for the quarter ending December 31, 2024 was $3.528B, a 8.06% decline year-over-year.
- Viatris revenue for the twelve months ending December 31, 2024 was $14.739B, a 4.46% decline year-over-year.
- Viatris annual revenue for 2024 was $14.739B, a 4.46% decline from 2023.
- Viatris annual revenue for 2023 was $15.427B, a 5.14% decline from 2022.
- Viatris annual revenue for 2022 was $16.263B, a 9.08% decline from 2021.
| Viatris Annual Revenue (Millions of US $) |
|
|---|---|
| 2024 | $14,739 |
| 2023 | $15,427 |
| 2022 | $16,263 |
| 2021 | $17,886 |
| 2020 | $11,946 |
| 2019 | $11,501 |
| 2018 | $11,434 |
| 2017 | $11,908 |
| 2016 | $11,077 |
| 2015 | $9,429 |
| 2014 | $7,720 |
| 2013 | $6,909 |
| 2012 | $6,796 |
| 2011 | $6,130 |
| 2010 | $5,451 |
| 2009 | $5,093 |
| Viatris Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2024-12-31 | $3,528 |
| 2024-09-30 | $3,751 |
| 2024-06-30 | $3,797 |
| 2024-03-31 | $3,663 |
| 2023-12-31 | $3,837 |
| 2023-09-30 | $3,942 |
| 2023-06-30 | $3,919 |
| 2023-03-31 | $3,729 |
| 2022-12-31 | $3,876 |
| 2022-09-30 | $4,078 |
| 2022-06-30 | $4,117 |
| 2022-03-31 | $4,192 |
| 2021-12-31 | $4,342 |
| 2021-09-30 | $4,537 |
| 2021-06-30 | $4,578 |
| 2021-03-31 | $4,430 |
| 2020-12-31 | $3,624 |
| 2020-09-30 | $2,972 |
| 2020-06-30 | $2,731 |
| 2020-03-31 | $2,619 |
| 2019-12-31 | $3,192 |
| 2019-09-30 | $2,962 |
| 2019-06-30 | $2,852 |
| 2019-03-31 | $2,496 |
| 2018-12-31 | $3,079 |
| 2018-09-30 | $2,862 |
| 2018-06-30 | $2,808 |
| 2018-03-31 | $2,685 |
| 2017-12-31 | $3,239 |
| 2017-09-30 | $2,987 |
| 2017-06-30 | $2,962 |
| 2017-03-31 | $2,720 |
| 2016-12-31 | $3,268 |
| 2016-09-30 | $3,057 |
| 2016-06-30 | $2,561 |
| 2016-03-31 | $2,191 |
| 2015-12-31 | $2,491 |
| 2015-09-30 | $2,695 |
| 2015-06-30 | $2,372 |
| 2015-03-31 | $1,872 |
| 2014-12-31 | $2,083 |
| 2014-09-30 | $2,084 |
| 2014-06-30 | $1,837 |
| 2014-03-31 | $1,716 |
| 2013-12-31 | $1,809 |
| 2013-09-30 | $1,767 |
| 2013-06-30 | $1,702 |
| 2013-03-31 | $1,632 |
| 2012-12-31 | $1,723 |
| 2012-09-30 | $1,802 |
| 2012-06-30 | $1,688 |
| 2012-03-31 | $1,584 |
| 2011-12-31 | $1,531 |
| 2011-09-30 | $1,576 |
| 2011-06-30 | $1,574 |
| 2011-03-31 | $1,449 |
| 2010-12-31 | $1,434 |
| 2010-09-30 | $1,355 |
| 2010-06-30 | $1,369 |
| 2010-03-31 | $1,292 |
| 2009-12-31 | $1,352 |
| 2009-09-30 | $1,264 |
| 2009-06-30 | $1,267 |
| 2009-03-31 | $1,210 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $13.595B | $15.427B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $150.904B | 28.19 |
| Elevance Health (ELV) | United States | $87.590B | 11.69 |
| CVS Health (CVS) | United States | $79.455B | 11.63 |
| Cencora (COR) | United States | $47.362B | 17.19 |
| DiDi Global (DIDIY) | China | $23.670B | 0.00 |
| Natera (NTRA) | United States | $20.908B | 0.00 |
| ICON (ICLR) | Ireland | $16.429B | 14.61 |
| Revvity (RVTY) | United States | $13.985B | 23.45 |
| BioMerieux (BMXMF) | France | $13.758B | 0.00 |
| Doximity (DOCS) | United States | $13.537B | 70.40 |
| Solventum (SOLV) | United States | $13.178B | 0.00 |
| Avantor (AVTR) | United States | $11.895B | 17.47 |
| CochLear (CHEOY) | Australia | $11.072B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.491B | 27.26 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $9.952B | 0.00 |
| HealthEquity (HQY) | United States | $9.484B | 47.58 |
| Charles River Laboratories (CRL) | United States | $8.719B | 16.52 |
| Sonic Healthcare (SKHHY) | Australia | $8.501B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $6.224B | 31.72 |
| Bausch + Lomb (BLCO) | Canada | $5.573B | 25.50 |
| Organon (OGN) | United States | $3.884B | 3.96 |
| Sotera Health (SHC) | United States | $3.814B | 20.40 |
| BrightSpring Health Services (BTSG) | United States | $3.382B | 71.93 |
| Surgery Partners (SGRY) | United States | $3.198B | 36.46 |
| Concentras Parent (CON) | United States | $2.951B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.613B | 0.00 |
| GeneDx Holdings (WGS) | United States | $2.610B | 316.67 |
| Ardent Health Partners (ARDT) | United States | $2.014B | 0.00 |
| PACS (PACS) | United States | $1.980B | 0.00 |
| Progyny (PGNY) | United States | $1.961B | 39.71 |
| Teladoc Health (TDOC) | United States | $1.961B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.845B | 48.40 |
| Premier (PINC) | United States | $1.690B | 10.82 |
| Agilon Health (AGL) | United States | $1.500B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.409B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.346B | 11.28 |
| CareDx (CDNA) | United States | $1.146B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $1.026B | 8.12 |
| Establishment Labs Holdings (ESTA) | $0.986B | 0.00 | |
| Embecta (EMBC) | United States | $0.798B | 5.47 |
| Auna S.A (AUNA) | Luxembourg | $0.598B | 0.00 |
| SBC Medicals (SBC) | United States | $0.484B | 0.00 |
| MultiPlan (MPLN) | United States | $0.472B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.472B | 0.00 |
| DocGo (DCGO) | United States | $0.453B | 17.08 |
| InnovAge Holding (INNV) | United States | $0.449B | 0.00 |
| Enhabit (EHAB) | United States | $0.406B | 35.09 |
| QDM (QDMI) | Hong Kong, SAR China | $0.335B | 8.78 |
| Nutex Health (NUTX) | United States | $0.314B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.253B | 0.00 |
| LifeMD (LFMD) | United States | $0.248B | 0.00 |
| Beauty Health (SKIN) | United States | $0.194B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.193B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.140B | 0.00 |
| Biodesix (BDSX) | United States | $0.122B | 0.00 |
| So-Young (SY) | China | $0.116B | 19.63 |
| Ascend Wellness Holdings (AAWH) | United States | $0.086B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.078B | 0.00 |
| ModivCare (MODV) | United States | $0.071B | 3.85 |
| Oncology Institute (TOI) | United States | $0.064B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 1.61 |
| OncoCyte (OCX) | United States | $0.046B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.035B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.020B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.015B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.014B | 0.00 |
| KindlyMD (KDLY) | United States | $0.013B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.007B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.006B | 0.00 | |
| XWELL (XWEL) | United States | $0.006B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |